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S100B is an EF-hand containing calcium-binding protein of the S100 protein family that exerts its biological effect by binding and affecting
various target proteins. A consensus sequence for S100B target proteins was published as (K/R)(L/I)xWxxIL and matches a region in the actin
capping protein CapZ (V.V. Ivanenkov, G.A. Jamieson, Jr., E. Gruenstein, R.V. Dimlich, Characterization of S-100b binding epitopes.
Identification of a novel target, the actin capping protein, CapZ, J. Biol. Chem. 270 (1995) 14651–14658). Several additional S100B targets are
known including p53, a nuclear Dbf2 related (NDR) kinase, the RAGE receptor, neuromodulin, protein kinase C, and others. Examining the
binding sites of such targets and new protein sequence searches provided additional potential target proteins for S100B including Hdm2 and
Hdm4, which were both found to bind S100B in a calcium-dependent manner. The interaction between S100B and the Hdm2 and/or the Hdm4
proteins may be important physiologically in light of evidence that like Hdm2, S100B also contributes to lowering protein levels of the tumor
suppressor protein, p53. For the S100B–p53 interaction, it was found that phosphorylation of specific serine and/or threonine residues reduces the
affinity of the S100B–p53 interaction by as much as an order of magnitude, and is important for protecting p53 from S100B-dependent down-
regulation, a scenario that is similar to what is found for the Hdm2–p53 complex.
© 2006 Elsevier B.V. All rights reserved.Keywords: S100B; Calcium-binding protein; S100 protein; p53; Hdm2; Mdm21. Introduction
There are several members of the S100 family of EF-hand
Ca2+-binding proteins that are distributed tissue-specifically in
humans [1–3]. S100 proteins were given this name because
they are soluble in 100% saturated ammonium sulfate [4]. One
member, S100B, is a 21.5 kDa symmetric homodimer that is
highly conserved (>97%) among mammals [1,4]. In general,
low levels of S100B have trophic effects, and higher levels are
problematic, resulting in uncontrolled cell growth [5–8].
Elevated levels of S100B are found in malignant melanoma
[9–12], renal cell tumors [13] and malignant mature T-cells⁎ Corresponding author. Tel.: +1 410 706 4354; fax: +1 410 706 0458.
E-mail address: dweber@umaryland.edu (D.J. Weber).
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doi:10.1016/j.bbamcr.2006.08.024(such as doubly negative CD4−/CD8− adult T-cells in leukemia
patients) [14]. Furthermore, S100B is up-regulated by cytokines
that stimulate gliosis such as interleukin-1β and the basic
fibroblast growth factor [15]. As is the case for S100B, a
number of other S100 proteins are regulated in a tissue-specific
manner [16]. S100A1, S100A6 (calcyclin), and S100B are
elevated significantly in metastatic human mammary epithelial
cells [17], and increased levels of S100A4 in transgenic mice
induce metastatic mammary tumors [18]. In the case of S100A4
(mts1), protein levels are controlled in benign cell lines via a
cis-acting element 1300 base pairs upstream of the rat
S100A4 start site [18], and expression of antisense RNA to
S100A4 suppresses metastatic potential for a high-metastatic
Lewis lung carcinoma [19]. Protein levels of S100B, S100A4,
and S100A6 correlate with malignant melanoma, so these S100
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S100 antibodies are used clinically to identify and classify
cancer in several tissues and cell types including brain, bladder,
breast, cervix, head and neck, intestine, kidney, larynx, lung,
lymph, mouth, skin, and testes among others [13,14,17,24–38].
More recently, S100B was shown to not only be a prognostic
marker, but that it also contributes to cancer progression in
malignant melanoma by interacting with p53 and inhibiting its
function as a tumor suppressor [24–26].
p53 is a transcription activator that signals for the up-
regulation of genes involved in cell cycle arrest and apoptosis
[27,28] and plays a pivotal role in the maintenance and
regulation of normal cellular functions. Its inactivation affects
cell cycle checkpoints, apoptosis, gene amplification, centro-
some duplication and ploidy [28–35]. If p53 is mutated, as
found in many human cancers, then the cell cycle proceeds
unregulated, cell growth proliferates, apoptosis pathways are
not induced, and proliferating cells transform into cancerous
ones [29,36]. On the other hand, if p53 levels are too high,
then phenotypes associated with aging and problems with skin
and bone occur [37]. Thus, p53 is highly regulated by
numerous post-translational modifications and via interactions
with other proteins (i.e. S100B, Hdm2, etc.) to regulate its
activity [31,38–41].
In its most active form, p53 is a dimer of dimers to form a
tetrameric X-type four-helix bundle in its C-terminus [42–44].
Upon binding specific DNA promoter sequences, the p53 tumor
suppressor activates the transcription of numerous downstream
target genes including a cyclin-dependent kinase inhibitor
(p21WAF/CIP1), cell cycle control proteins (cyclin G, GADD45),
genes involved in apoptosis (i.e. Bax), and a gene product,
Mdm2 (or Hdm2 for the human protein), which in turn
negatively regulates p53 protein levels inside the cell as part of a
feedback loop to keep p53 protein levels in check [27,28,45].
Hdm2 is an E3 ligase that down-regulates p53 by an ubiquitin-
mediated pathway, which is dependent on the phosphorylation
state of p53 in the N-terminal transactivation domain. The 3D
structure of the N-terminal domain of Hdm2 somewhat
resembles EF-hand proteins, despite the fact that it does not
bind calcium [46]. A structurally related protein, Hdm4 (also
called Mdmx or Mdm4 for the murine protein) also binds to the
same region of p53 and inhibits its activity under certain
conditions; however, unlike Hdm2, Hdm4 does not have
significant ubiquitin ligase activity [47]. Directly C-terminal
to the tetramer domain on p53 is a basic region termed the
“extreme C-terminus” or the “C-terminal negative regulatory
domain”, which is unstructured when free in solution, but is
helical when bound to the calcium-binding protein S100B [48].
If the negative regulatory domain is unmodified, p53 has
lowered transcription activation activity (i.e. latent state). In
fact, deletion of the last 30 residues, covalent modification, and/
or binding of antibodies to this domain activates p53 by
preventing non-specific DNA binding and/or perhaps by
inhibiting S100B binding [49,50]. In this study, it is
demonstrated that phosphorylation of the C-terminus does
indeed inhibit S100B binding and is analogous to how p53 is
protected from another known negative regulator of p53,namely Hdm2. Furthermore, it is shown that S100B interacts
directly with Hdm2 in a calcium-dependent manner. Thus, it is
possible that S100B and Hdm2 work concertedly to down-
regulate p53, which is discussed.
2. Materials and methods
2.1. Chemicals
All chemicals and reagents were ACS grade or higher and purchased from
Sigma-Aldrich unless otherwise indicated. 15NH4Cl was purchased from
Cambridge Isotope Laboratories (Woburn, MA). All buffers were passed
through Chelex-100 resin to remove trace metals.
2.2. Peptides and S100B protein preparation
Unlabeled and 15N-labeled S100B were overexpressed and purified from
E. coli as described previously [51,52]. Using phage display, Ivanenkov et al.
defined a target sequence ([K/R]-[L/I]-x-W-x-x-I-L) and identified a 12 residue
peptide, termed TRTK-12, which binds S100B and most closely resembles a
sequence (residues 265–276) in the actin capping protein, CapZ (62). By
expanding protein database searches to include a larger number of protein
sequences ([K/R]-[L/I]-[P/S/N/D]-[W/L/I]-[S/D/L]-x-[L/I]-[L/F]), additional
S100B targets were identified (Table 1). Peptides based on such searches were
produced by Bio-Synthesis, Inc. (Lewisville, Texas) using solid-state peptide
synthesis and their purity were >95% as determined by HPLC and mass
spectrometry unless indicated otherwise (see Table 1 for the amino acid
sequences). The concentration of peptides containing tryptophan were deter-
mined using the extinction coefficient for tryptophan (ε280=5690 cm
−1M−1), the
concentration of the FITC labeled p53 peptide, FITC-p53367–393 was determined
using the extinction coefficient for FITC (ε494=72,000 cm
−1 M−1), while the
concentration and composition of the other peptides were confirmed by amino
acid analysis (Bio-Synthesis, Inc., Lewisville, Texas). TheN- and C-termini were
acetylated and amidated, respectively, for TRTK-12 (Biopolymer Lab, U. of
Maryland, Baltimore, MD), F385Wp53367–388, RAGE, p53367–388, p53321–346,
Hdm225–43,Hdm425–43, andPAK1252–271 peptides.TheN-terminusof p53367–393
was acetylated as were the N-terminus of the phosphorylated serine/threonine
version of that peptide, S376 Phos (p53367–393 phosphorylated at Ser-376), T377
Phos (p53367–393 phosphorylated at Thr-377), S378 Phos (p53367–393 phosphor-
ylated at Ser-378), S392 Phos (p53367–393 phosphorylated at Ser-392), and
acetylated lysine version of p53367–393, K382 Ac (p53367–393 acetylated at Lys-
382), while for the FITC-p53 peptide, the N-terminus only of p53367–393 is
conjugated to FITC.TheC-terminus ofRKLLW(AlexisBiochemical, SanDiego,
CA) was amidated. The termini of Nt, an Y11Wmutant of neurotensin (residues
8–13; American Peptide, Sunnyvale, CA), XP-1, the xenopsin related peptide 1
(Bachem Inc.), PKC19–36 (Sigma-Aldrich), andPKCA25S (Sigma-Aldrich)were
not modified at either the N- or the C-termini.
2.3. Fluorescence spectroscopy
The Ca2+-dependent interaction of peptides with wild-type and mutants of
S100B were performed using fluorescence spectroscopy techniques on an SLM-
Aminco Bowman series 2 (Thermo, Asheville, NC) or a Carey Eclipse (Varian
Inc., Palo Alto, CA) fluorescence spectrophotometer with the temperature
maintained at 37 °C. For low salt conditions listed in Table 1, the buffer
contained 10 mM TES, pH 7.2, 15 mM NaCl, and 10 mM CaCl2; the high salt
buffer contained 100 mM KCl in addition to that listed in the “low salt” buffer.
For the Trp containing peptides (F385Wp53367–388, TRTK-12, RAGE, RKLLW,
XP-1, and Nt), increased fluorescence emission from the tryptophan residue at
338 nm was monitored upon titration of S100B with excitation at 295 nm. In all
of the titrations, the titrant and reactant were prepared with equal concentrations
of peptide (up to 4 mM), so no corrections for dilution were necessary.
Fluorescent polarization measurements during competition binding studies was
used to monitor the binding of peptides to S100B using the same low and high
salt conditions except with 1 μM FITC-p53367–393. Polarization readings of
FITC-p53367–393 were monitored is such assays using an SLM-Aminco series 2
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85 nm and an emission wavelength of 520 nm. The binding data were fit using a
single site binding model with Origin software (OriginLab Corp., Northampton,
MA) and one peptide bound per S100B subunit. For fluorescent intensity
competition assays with the F385Wp53367–388 peptide, non-fluorescent peptide
was used to compete F385Wp53367–388 with the upper limit for the dissociation
constant (KD) being determined using the Cheng–Prusoff equation; KD=[I]50 /
(1+ [F385W]/F385WKD) where [I]50 is the concentration of the unlabeled
peptide at 50% inhibition and F385WKD is the dissociation constant of the
S100B-F385Wp53367–388 complex (in low salt F385WKD=3.9±0.3 μM; Table 1)
[53]. For fluorescence polarization competition assays, an equation derived by
Nikolovska-Coleska et al. was used for determination of the KD, as previously
described [54], using; KD=[I]50/([L]50 /
FITCp53KD+[P]0 /
FITCp53KD+1) where
[I]50 is the concentration of the unlabeled peptide at 50% inhibition, [L]50 is the
concentration of the free FITC-p53 at 50% inhibition, [P]0 is the concentration
of the free protein at 0% inhibition, and FITCp53KD is the dissociation constant
of the S100B-FITC p53367–393 complex (in high salt FITCp53KD=99.2±7.7 μM;
Table 1) [54].
2.4. Isothermal titration calorimetry (ITC)
Heat changes during the titration of the Hdm225–43, Hdm425–43, PAK1252–271,
and F383Wp53367–388 peptides into Ca2+-S100B was measured using a VP-ITC
titration microcalorimeter (MicroCal, Inc., Northhampton, MA) as done
previously [55]. For each titration the sample cell (1.4 ml) contained 10 mM
TES, pH 7.2, 15 mM NaCl, and 10 mM CaCl2, 100 mM KCl, and 0.1 mM
S100B while the reference cell contained water with all solutions being
degassed under vacuum and equilibrated at 37 °C prior to titration. Upon
equilibration, a 1.25–1.8 mM peptide solution prepared in the same buffer
without S100B was injected in 29×5 μL aliquots using the default injection
rate with a 300 s interval between each injection to allow the sample to return
to baseline. The resulting titration curves were corrected for the protein free
buffer control and analyzed using the Origin for ITC software supplied by
MicroCal (Northampton, MA).Notes to Table 1:
a The underlined amino acids are within 6 Å of residues in S100B based on th
of p53367–388 [86], TRTK [88], and Ndr [63] peptides bound to Ca2+–S100B. Th
was observed, and ND was used to indicate that the peptide binds to S100B b
b Binding affinities in “low salt” conditions were performed by fluorescence spe
15 mMTES, pH 7.2, 10 mMCaCl2, 15 mMNaCl, at 37 °C except for Ndr that was de
by NMR in 20 mM Tris, pH 7.5, 5 mM CaCl2, 30 mM KCl, and 10 mM DTT at 37
c The TRTK-12 peptide is derived from residue 265 to 276 of the actin capping
McClintock et al. report that TRTK-12 binds S100B with a KD=0.27±0.03 μM in
d The buffer conditions were 10 mM TES, pH 7.2, 10 mM CaCl2, 15 mM NaCl,
e Fernandez-Fernandez et al. [90] reported binding for p53325–355, p53325–339, p
99.2 mM NaCl, 1 mM DTT. This group also determined the binding affinity for p5
(KD=102±3 μM) as reported here for the “high salt” buffer.
f The domain encompassing the tetramerization and C-terminal regulatory region
likely the tetramerization site (residues 325 to 355) and in the C-terminal regulatory
g The p53367–393 peptide was covalently modified in the C-terminal region of p53 t
and acetylation (Ac), which are italicized.
h NMR experiments show the PKC19–36 and p53321–346 bind S100B in 10 mM TE
determined.
i A peptide from rod outer segment membrane guanylate cyclase type 1 (ROS-GC
group, from a Cys residue added to the N-terminal of the peptide, and surface plasm
j The C-terminal domain of human p53 (residues 319–393) was immobilized to
determine the binding affinity to S100B [92]. Subsequently, two shorter peptides deri
off S100B; the KD for this competition was not reported (ND). While the tetrameri
terminal peptide, Mu p53 357–381, was not able displace S100B at concentrations as h
differs from the human p53 peptide, p53367–388 at three positions (L383M, residue
binding S100B. The Mu p53321–346 peptide was mutated at two positions (Y321W,
k S100B inhibits the PKCα phosphorylation of these peptides as it does the p533
l The MARCKS peptide (residues 152 to 172) contain a PKCα phosphorylation si
undetermined [94].
m Baudier et al. showed the interaction of Tau peptide (residues 337 to 370) with S1
these authors also report that Melittin, a 26 amino acid long peptide from bee venom, a2.5. NMR spectroscopy
NMR spectra were collected at 37 °C with either a Bruker DMX600 NMR
spectrometer (600.13 MHz for protons) or a Bruker AVANCE 800 NMR
spectrometer (800.27 MHz for protons) equipped with four frequency channels
and a triple-resonance z-axis gradient 5mMcryoprobe.All proton chemical shifts
are reportedwith respect to the H2O or HDO signal taken to be 4.658 ppm relative
to external TSP (0.0 ppm) at 37 °C. The 15N chemical shifts were indirectly
referenced using the following ratios of the zero-point frequencies at 37 °C:
0.10132905 for 15N [56–58]. Uniformly 15N-labeled S100B was used to collect
the 2D 1H,15N-fast HSQC [59] during the titration of peptides into Ca2+-S100B
and changes in S100Bbackbone15N and1Hweremonitored and readily assigned.
Typical NMR samples contained 0.05–0.50 mM S100B, 0–5.0 mM peptide,
10 mMTES, pH 7.2, 15 mMNaCl, 10 mMCaCl2, 0.34 mMNaN3, 5–10%D2O.
2.6. Lambda2Hybrid protein association assay
Under normal conditions, double infections of E. coli by lambda phage do not
occur; however, expressing protein binding partners fused to the C-terminus of
phage D protein enables the two phages to associate and simultaneously infect a
cell. By using modified lambda phage, which contains different antibiotic
resistances, the interaction and formation of multi-lysogens will result in double
antibiotic resistant colonies (Cmlr/Kanr). Such colonies can then be quantified as
the formation of specific protein–protein complexes; furthermore, disruption of
such protein–protein interactions are also performed in inhibition assays since the
interaction between the two phages is done in vitro. Construction of the S100B
(λD-S100BC), wild type human p53 (λD-p53K), dimeric p53 mutant (λD-
p53K
MLQR) [60] andHdm2 (λD-Hdm2K) display phages were done according to the
method of Bair, et al. (in preparation). For the association assay, the phage fusions
being tested are first diluted separately then combined at a ratio of 1:1 in the reaction
tube, mixed gently and incubated for 5 min at R/T. To this, 100 μL SABE buffer
(20 mM Tris, pH 7.4, 10 mM CaCl2, 10 mMMgSO4, 100 mM NaCl, and 5 mM
EDTA) with or without inhibitor is added with gentle mixing and incubated for
10 min at room temperature. At that time, 1×108 mid-log phase E. coli C600e observance of NOE correlations for determining the NMR based structures
e short hand notation NB was used to indicate “No binding” to the peptide
ut that the exact KD is “not determined”.
ctroscopy or with isothermal titration calorimetry (ITC; for TRTK-12) with in
termined by Bhattacharya et al. by plotting the chemical shift changes determined
°C [63].
protein CapZ peptide, which was discovered by Dimlich et al. [62]. Previously,
50 mM Tris, 50 mM KCl, and 1 mM CaCl2 at pH 7.2 [65,88,89].
100 mM KCl, at 37 °C.
53340–351, p53305–322, and p53293–393 in 25 mM Tris, pH 7.5, 10 mM CaCl2,
3367–393 under these conditions, which gave the same affinity for Ca2+–S100B
of p53 was synthesized and two S100B binding sites were detected; these are
region (residues 367 to 393) [90].
o mimic covalent modifications that occur in vivo such as phosphorylation (Phos)
S, pH 7.2, 10 mM CaCl2, 15 mM NaCl, at 37 °C, but the exact KD was not
1; residues 962 to 981) was immobilized to a sensor chip via the cysteine thiol
on resonance (SPR) was used to determine the binding affinity [91].
a sensor chip by random coupling of its amine groups and SPR was used to
ved from mouse p53, Mu p53321–346 and Mu p53357–381, were added to compete
zation domain peptide, Mu p53321–346, was able to compete off S100B the C-
igh as 1 μM. Note that the sequence of the mouse p53 peptide, Mu p53357–381,
colored in gray; R379H, F385K; human numbering), which are important for
F322W; human numbering).
67–388 peptide by binding the peptide [93].
te whose phosphorylation is inhibited due to binding to S100B but the affinity is
00B and the Tau337–370 peptide contains a PKCα phosphorylation site. In addition,
lso binds S100B, but for both of these peptides, no KD is reported [95].
1288 P.T. Wilder et al. / Biochimica et Biophysica Acta 1763 (2006) 1284–1297(supE+) cells are grown in LB supplementedwith 0.4%maltose and 10mMCaCl2.
After 45–60 min at room temperature, the entire reaction is plated on one 100 mm
LB agar plate containing 12 μg/ml chloramphenicol and 25 μg/ml kanamycin and
incubated overnight at 32 °C, after which time, the number of colonies are counted.
2.7. GST-Hdm2 pull down assay
The GST-Hdm2 expression vector was prepared in the laboratory of Allan
M. Weissman (NCI, NIH, Bethesda, MD 20892) and provided by Shengyun
Fang (The University of Maryland School of Medicine, Baltimore, MD). This
vector was used to produce glutathione S-transferase (GST) fusions of Hdm2
with a N-terminal GST tag in E. coli BL-21(DE3)star cells (Novagen Inc.) that
were grown at 37 °C until mid-log phase (i.e. OD600 ∼ 0.8–1.0), induced with
0.84 mM IPTG for 1–1.5 h after which the cells were centrifuged 5000×g in a
GS-3 rotor using a RC2-B Superspeed centrifuge (Thermo, Asheville, NC) and
the pellet stored at −80 °C until use. Bacterial pellets were suspended in 1 ml per
gram with 50 mM Tris, pH 7.4, 150 mM NaCl, 5 mM DTT, 2 mM phenyl-
methylsulfonyl fluoride (PMSF) to which 0.08 ml per gram pellet of 10 mg/ml
lysozyme was added for 15 min on ice. Then, 300 μl DNase solution (1 mg/ml)
and 300 μl 4.9 M MgCl2 were mixed for 15 min and lysis was completed by
probe sonication. The sonicate was clarified by centrifugation at 4 °C for 45 min
at 27,000×g in SS-34 rotor (Sorvall), the protein was captured on glutathione
agarose beads (Novagen) using batch purification, and the beads were washed
three times in 50 mM Tris, pH 7.4, 150 mMNaCl. GST-Hdm2 beads and control
beads were then blocked with 5% BSA in the same buffer for 30 min at 37 °C,
centrifuged briefly to pellet beads then washedwith the same buffer without BSA
with either 5 mM CaCl2, no CaCl2, or no CaCl2 plus 5 mM EDTA and pelleted
again before adding 10 μg S100B in the same buffer for 1 h at room temperature.
The beads were then washed three times in the same buffer, without S100B, to
remove unbound protein before the S100B was eluted with 25 μl EDTA
(500 mM). Samples were run on an 18% SDS-PAGE, blotted, and detected using
S100B rabbit polyclonal antibody (Research Diagnostics Inc., Flanders, NJ) at
1:1000 dilution as done for the cellular p53 assays outlined below.
2.8. Cellular assays of p53 down-regulation by S100B
Human large cell lung carcinoma cells, H1299, were grown in Minimum
Essential Medium (Invitrogen Inc.) containing 10% fetal bovine serum. The p53Fig. 1. Thermodynamic binding data showing that peptides derived from Hdm2 resid
in the presence of calcium. Isothermal titration calorimetry (ITC) data demonstrating
S100B and Hdm425–43 in 10 mM TES, pH 7.2, 15 mM NaCl, and 10 mM CaCl2, 1expression vector (pCMV3-p53) was provided by Bert Vogelstein (Johns
Hopkins University, Baltimore, MD). Using this wild-type p53 expression
vector and the QuikChange site-directed mutagenesis kit (Stratagene Inc.), the
phosphorylation site single and double mutant constructs were engineered
including pCMV3.p53 S376A(TCT to GCC), pCMV3.p53 T377A (ACC to
GCC) and pCMV3.p53 DM (S376AT377A). The pCMV3 empty vector, which
was used as a control in several experiments, was purchased (Strategene Inc.).
The pCMV-Myc empty vector was purchased (Clontech Inc.), and the gene for
rat S100B was cloned into the SalI/XhoI sites. To examine the effects that
S100B has on p53 protein levels and function, H1299 cells were transiently
transfected with the fixed amount of plasmid (12 μg) by the Fugene 6
transfection reagent (Roche Diagnostics) according to the manufacturer's
recommendation such that the S100B plasmid was in excess (9 μg) versus the
p53 plasmid (3 μg). Next, western blot analyses were performed on 20 μg of
H1299 protein extract after the cells were lysed in RIPA buffer (50 mM Tris–
HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate,
0.1% SDS, 1 mM phenylmethylsulfonyl fluoride, 2 μg/ml leupeptin, 5 mM
DTT, 50 mM NaF, 5 mM EDTA). The proteins were analyzed on a 12%
polyacrylamide gel, transferred on nitrocellulose, and reacted with either p53
mouse monoclonal antibody (DO-1, Oncogene Research Products, Boston, MA)
at 1:1000 dilution, S100B rabbit polyclonal antibody (Research Diagnostics
Inc., Flanders, NJ) at 1:1000 dilution, p21 rabbit monoclonal antibody (Zymed
Laboratories Inc.) at 1:1000, or actin mouse monoclonal antibody (Oncogene
Research Products) at 1:5000 dilution to control for even protein loading. The
blots were then reacted with their respective secondary antibodies conjugated to
horseradish peroxidase and reacted with a chemiluminescence substrate (ECL,
GE Healthcare) as recommended by the manufacturer.3. Results
3.1. Binding of S100B to peptide and protein targets including
p53, Hdm2, and Hdm4
Upon the addition of calcium, helix 3 of S100B rotates ∼90°
and exposes a site that binds target proteins and peptides [61].
Using phage display, Ivanenkov et al. defined a S100B targetues 25 to 43 (Hdm225–43) and Hdm4 residues 25 to 43 (Hdm425–43) bind S100B
the calcium-dependent interaction between (A) S100B and Hdm225–43, and (B)
00 mM KCl, and 0.1 mM S100B at 37 °C.
1 Resonances of phenylalanine-14 in S100B likely shift during the titrations
with the peptides because of a long-range structural perturbation rather than
from a direct interaction with the S100B-binding peptides.
Fig. 2. GST-Hdm2 pull down assay showing the Ca2+-dependent interaction between S100B and Hdm2. An N-terminal GST tagged Hdm2 was immobilized on
glutathione beads and S100B (±EDTA) or Ca2+-S100B was loaded and washed extensively with buffer (without S100B). A subsequent wash with EDTAwas used to
release any S100B bound to the Hdm2-linked column. Only in the presence of Ca2+ is S100B able to bind immobilized GST-Hdm2 (lane 2). No binding was observed
without calcium present (lane 1) or in controls with EDTA in the loading buffer (lanes 3, 6), GST-bound beads (4, 5, 6) or with beads alone (data not shown).
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peptide, termed TRTK-12, which binds S100B and most closely
resembles a sequence (residues 265–276) in the actin capping
protein, CapZ [62] (Table 1). By expanding the search to include
a larger number of protein sequences ([K/R]-[L/I]-[P/S/N/D]-
[W/L/I]-[S/D/L]-x-[L/I]-[L/F]), additional S100B targets were
identified. Of particular interest was the discovery that S100B
associates rather tightly to peptides derived from Hdm2
(KD=3.1±0.4 μM; Fig. 1A; Table 1) and Hdm4 (also termed
MdmX; KD=0.4±0.02 μM; Fig. 1B, Table 1) since these two
proteins are involved in the regulation of p53. In addition to
these two peptides, several other peptides were also found to
bind S100B in the presence of calcium including new data
reported here for peptides derived from p53, phosphorylated
p53, human RAGE, neurotensin (nt), cathepsin L inhibitor
(RKLLW), and a peptide derived from the regulatory domain of
protein kinase Cα (0.3 μM<KD<60 μM; Table 1). That Hdm2
does indeed bind S100B in a calcium-dependent manner was
further supported by GST-pull down experiments using full-
length S100B and Hdm2 protein constructs (Fig. 2). It should be
pointed out that the Hdm2 peptide, which binds S100B (Table
1), is derived from a region of the protein that is not exposed in
existing X-ray or NMR structures (PDB codes 1Z1M, 1T4F,
2AXI, and 1RV1). Therefore, the interaction observed between
S100B and full-length Hdm2 (Fig. 2) must either occur as the
result of exposing this Hdm2 peptide site upon binding or
alternatively S100B interacts with yet another region of Hdm2.
Upon examination of Table 1 and NMR solution structures
of S100B–peptide complexes [48,63–65], there is not a very
well defined consensus sequence for S100B targets, which may
be the reason why S100B is able to bind such a diverse class of
proteins. The one common element in all of the S100B–
peptide structures completed to date (TRTK-, p53367–388-, and
Ndr-S100B) and in all of the sequences of the S100B target
peptides is that there is a hydrophobic residue on the target
peptide (W, F, or L residues) that interacts with several
hydrophobic residues on helices 3 and 4 of S100B (highlighted
in gray in Table 1). A second component of a S100B target
protein is the presence of several positively charged Lys and
Arg residues on either side of the hydrophobic residue. Such
basic residues likely form salt bridge(s) with acidic residues on
S100B; however, there is a great deal of variation in the
position of basic residues in the peptides' sequences (coloredblue in Table 1). For example, ionic interactions in the S100B–
p53 structure (i.e. between Glu-45 and Glu-86 of S100B and
Arg-379 and Lys-386 on p53, respectively) are observed in this
3D structure and are further supported by the observation that
p53367–388 binds Ca2+–S100B nearly 5-fold weaker at elevated
salt concentrations; similarly, TRTK-12, which also has
potential salt bridges binds S100B 2.5-fold weaker at higher
salt. The lesser effect on TRTK-12 is likely due to the
extensive number of hydrophobic interactions observed in the
structure of this peptide bound to S100B (Table 1) [48,64].
Although not yet supported by 3-dimensional structural data, it
appears that the presence of positively charged arginine and
lysine flanking both sides of the hydrophobic residue may
tighten the interaction since the peptides that only have a
positive charges on one side (i.e. RKLLW, XP-1, and Nt) bind
more weakly; however, it should also be noted that these
peptides are shorter as well, so the decreased affinity could also
be due to lack of another interaction(s).
3.2. Chemical shift perturbations in S100B caused by target
peptide binding
To further explore interaction of S100B with various target
peptides, changes in the chemical shifts of S100B backbone 1H
and 15N between Ca2+-bound to target peptide–Ca2+-bound
were recorded (Fig. 3). The amino acids in S100B where
chemical shift values are perturbed upon binding of different
target peptides are very similar indicating that the target peptides
as a whole interact with similar residues on S100B (Fig. 3);
although, it should be noted that chemical shift changes in a
protein may be the result of direct interaction of a ligand with
amino acid residues and/or by changes in the overall protein
structure caused by peptide binding. For the five S100B–peptide
interactions examined here (Fig. 3), significant chemical shift
perturbations and/or residues that are exchange broadened (i.e.
resonances that disappear in peptide titrations) occur for residues
in loop 2, termed the hinge region (S41, F43, L44, E45), helix 3
(V52, V53, V56, T59), the C-terminus of helix 4 (S78–F88), and
in helix 1 (F14). With Phe-14 as an exception1, most of these
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peptide complexes are also found to interact directly in the
S100B–p53 peptide complex (via intermolecular NOE correla-tions) including residues in the hinge region of S100B (L40,
H42, L44, I47), helix 3 (V52, V56), and in C-terminus of helix 4
(M79, V80, A83, F87) [48]. Interestingly, when the amino acid
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hydrophobic nature of the residues in S100B that interact with
the target peptides are conserved throughout the family of 22
related S100 proteins including L40 (95.0%), L44 (85.0%), V52
(75.0%), V53 (100.0%), V56 (90.0%), V80 (100.0%), A83
(75.0%), F87 (60.0%) and F88 (65.0%). However, the
negatively charged residues that interact with specific peptide
targets are not well conserved. For example, the charged residues
of S100B that interact with p53367–388 are minimally conserved
including E45 (15.0%) and E46 (25.0%) or E86 (50.0%), and in
some cases, other S100 proteins have these analogous positions
(i.e. E45, E46, and E86 in S100B) replaced with oppositely
charged Lys or Arg residues, 35.0%, 15.0%, and 30.0% of the
time, respectively. It is these variations in the charged residues
that could perhaps give rise to binding specificity among various
S100 proteins.
3.3. Do full-length Hdm2 and p53 interact with the
well-defined peptide binding site on S100B?
Data in Table 1 and several previously published studies
have demonstrated that S100B interacts with p53 including full-
length p53 [66] and peptides derived from the C-terminal region
of p53 [48,67–69]. However, the binding site for full-length p53
on S100B has not yet been fully established. Nor has it been
established whether Hdm2 binds to this same site on Ca2+-
bound S100B or to another yet to be discovered site. To answer
this question, a newly developed method for examining
protein–protein interactions was employed, which was devel-
oped by Dr. Sankar Adhya and colleagues at the National
Cancer Institute, and termed the Lambda-2-hybrid method.
Specifically, competitive inhibition experiments using the
Lambda-2-hybrid methodology (Bair et al., in preparation)
confirmed that full-length p53 binds to a site on S100B that
overlaps a small molecule inhibitor binding site (SBi1) and
the TRTK-12 peptide site on S100B. In both of these
experiments, recombinant lambda phage expressing S100B
(λD-S100B) interacts with lambda phage expressing p53 (λD-
p53) or a dimeric mutant of p53 (λD-p53MLQR; [60]) each of
which are fused to the C-terminus of the phage major capsid
protein D. Importantly, the S100B–p53 interactions detected
by this method could be inhibited specifically by either the
TRTK-12 peptide or by the S100B small molecule inhibitor,
SBi1 (Fig 5). Similarly, a lambda phage expressing Hdm2
(λD-Hdm2) interacts with λD-S100B and this Hdm2-S100B
protein–protein interaction was also inhibited by TRTK-12. It
was also demonstrated that Hdm2 display phage, λD-Hdm2k,
does interact with the λD-p53 and λD-p53MLQR phageFig. 3. Changes in chemical shifts for 1H–15N correlations in Ca2+-bound S100B up
shift perturbations upon binding (A) p53367–388, (B) p53321–346, (C) TRTK-12, (D
combined backbone 1H and 15N chemical shift perturbations upon peptide binding
severely exchanged broadened. Correlations for H42, L44, E45, and E86 for the p53
broadened upon binding, so Δδ values could not be determined for these residues. To
p53367–388-bound S100B (PDB 1DT7) with the p53367–388 peptide in each subunit re
significant chemical shift perturbations (i.e.Δδ values that are greater than that obser
observed during the peptide titration. The residues that were perturbed (in yellow) are
(red); the other S100B subunit (blue) and the Ca2+ ions (gray spheres) are also illusindicating that this dimeric construct of p53 is folded
correctly and, as expected, this interaction was not affected
by the addition of up to 384 μM TRTK-12. SBi1 (80 μM), a
small molecule that binds S100B [70], was also able to inhibit
binding of λD-S100B to λD-p53MLQR (84%) and the binding
of λD-S100B to λD-Hdm2 (46%). Together, these competi-
tion binding data illustrate that full-length Hdm2 and full-
length p53 each bind a site on S100B that comprises the
TRTK-12 peptide and the S100B small molecule inhibitor,
SBi1 site(s) [64,65,70,71].
3.4. Covalent modifications in the C-terminal negative
regulatory domain of p53 protects the tumor suppressor from
binding to S100B
It is now established that p53 is protected from Hdm2-
dependent degradation via phosphorylation in its N-terminal
transactivation domain [72,73]. Based on the 3D structure of
S100B bound to the C-terminus of p53, it was predicted that
phosphorylated and perhaps acetylated p53 would not bind
Ca2+-S100B as tightly as unmodified protein [48]. This indeed
turned out to be the case since S100B was found to bind p53
peptides, phosphorylated at residues that were in the S100B–
p53 peptide interface (S376, T377), more weakly than a
corresponding p53 peptide that was not covalently modified
(Fig. 6; Table 1); whereas, phosphorylation of Ser-378, which is
facing solution in the S100B–p53 peptide structure had little or
no effect on binding (Table 1; Fig 6). Similarly, steric hindrance
or loss of a salt bridge due to the acetylation of p53 Lys-383
could explain why the acetylated version of the p53 peptide also
inhibits S100B binding by more than 10-fold (Fig. 6A and B).
Furthermore, it is likely that covalent modifications such as
phosphorylation and perhaps acetylation stabilize the structure
of the extreme C-terminus, as predicted by Arrowsmith et al.
[49], and as supported by data showing that phosphorylated p53
is more stable and binds DNA more tightly in vitro [74].
Further evidence for this “p53 protection model” is provided
by our own earlier studies with the Δ30 p53 mutant (p531–363;
ΔNRD), which has the C-terminus of p53 removed [25]. In this
study, we showed that the Δ30 p53 mutant was down-regulated
by S100B to a larger degree than that of full-length p53 in
H1299 cells [25]. Here, it is thought that the inability of theΔ30
p53 mutant to get sufficiently phosphorylated leaves this
construct open to S100B binding to the tetramer domain, as
observed previously ([67]; Table 1), and subsequently to
S100B-dependent p53 degradation. Based on this model, we
anticipated that the S376A and the T377A p53 mutants (and
perhaps others) will be more susceptible to S100B-dependenton binding several target peptides. Similar residues in S100B undergo chemical
) PKC19–36 or (E) the RKLLW peptides. The bar graphs on the left show the
to Ca2+–S100B except for residues G22, D23, K24, I47, and Q50, which are
321–346 peptide, F43 for TRTK-12, and M79 and V80 for the PKC19–36 peptide
the right of each bar graph are ribbon diagrams of the 3D solution structure for
moved; these ribbon diagrams show (in yellow) the amino acid residues having
ved for F14) and/or residues for which extreme exchange broadening effects was
shown for titrations with each peptide, respectively, on only one S100B subunit
trated.
Fig. 4. Sequence alignment of the human S100 protein family based on their homology to S100B. The residues highlighted in gray match the S100B protein sequence
exactly; residues highlighted in yellow are conserved hydrophobic residues; residues highlighted in red are conserved negatively charged residues. Shown in blue are a
few positively charged residues that appear in regions of the protein that are more often negatively charged to emphasize a change in charge in some S100 family
members at that position. In addition, downward pointing arrows are used to identify the position of the Ca2+-binding ligands for both the N-terminal S100-EF-hand
(the pseudo EF-hand) and the more typical C-terminal EF-hand. Some S100 proteins are too long for this table, so parts of their sequences are omitted as follows: for
S100A5, *=MPAAWILWAHSHSE; for S100A9, #=HKPGLGEGTP; for S100A14, ψ=MGQCRSANA.
1292 P.T. Wilder et al. / Biochimica et Biophysica Acta 1763 (2006) 1284–1297degradation than wild-type and S376A p53. In H1299 cells, this
indeed turned out to be the case for the T377A mutant (Fig 6C).
However, no additional effect on p53 degradation was observed
when the T377A p53 and S376A+T377A double mutant were
compared, which is evidence that the mutation at Thr-377 is
more deleterious for S100B-dependent degradation of p53 in
cells, and are consistent with the hypothesis that phosphoryla-
tion of Thr-377 in p53 is an important phosphorylation site for
protecting p53 from S100B. This idea is also in agreement with
cellular reporter gene assays from Youmell et al., done with full-
length p53, which show that mutating T377 is the most
deleterious PKC site mutant when p53 transcription activation
activity is measured; although, a small effect was also observed
for the S376 mutant [75]. The differences observed in
comparisons of the peptide-binding data (Table 1) to the
cellular assays done with full-length p53 (Fig. 6) are suggestive
that perhaps full-length p53 binds S100B slightly differently
than found in the S100B–p53 peptide complexes, although this
remains to be determined more rigorously. Nonetheless, it is
important to note that the absence of the extreme C-terminus
(Δ30 p53; [25]) and/or the lack of a phosphorylation site in the
C-terminus of p53 (at Thr-377) does reduce the stability of p53
in treatments with S100B (Fig. 6C) and is consistent with
previously measured transcription activation assays done with
the same phosphorylation mutants performed by Youmell et al.
[75].4. Summary
A schematic is presented (Fig. 7) that summarizes how
calcium-loaded S100B and Hdm2 participate in the down-
regulation of the tumor suppressor protein, p53. Furthermore,
feedback loops are in place such that the tumor suppressor
protein levels are kept under tight regulatory control (Fig. 7).
Evidence of an S100-p53 interaction in vivo was provided by
co-immunoprecipitation (co-IP) experiments with S100B done
in human primary malignant melanoma cancer cells [76].
Similar co-IP experiments were also demonstrated for the
S100A4–p53 interaction [24]. While most proteins that bind or
modify the C-terminus of p53 activate the tumor suppressor, the
opposite effect was observed for both S100A4 and S100B; in
both cases, DNA binding to p53 in gel shift assays is decreased,
and correspondingly, p53 function as a transcription activator is
decreased when bound to S100 protein [24,25]. In the case of
S100A4 (mts1), the S100-dependent affect on p53 transcription
activation varied for some genes and showed a time and cell-
density dependence [24,77]. For S100B, p53 protein levels and
downstream effector genes, Hdm2 and p21 were also measured
after human large-cell lung carcinoma cells (H1299; p53−/−)
were transiently co-transfected with p53 and S100B expression
vectors [25,78]. As expected, expression of p53 triggered
expression of Mdm2 and p21, but co-expression with the
S100B protein markedly reduced the accumulation of p53,
Fig. 5. The p53–S100B, p53–Hdm2, and the Hdm2–S100B interactions are
detected using the Lamda2hybrid methodology and then monitored using
competition studies with a S100B binding peptide, TRTK-12. Recombinant
lambda phage expressing S100B (λD-S100BC) and a mutant of p53 that forms
dimer rather than tetramers (λD-p53MLQRK) are fused to the C-terminus of the
phage major capsid protein D, one containing the CmlR and the other the KanR
gene, respectively. Thus, S100B and p53MLQR interact as is necessary to produce
double antibiotic resistant colonies (red triangles). This S100B–p53MLQR
interaction was inhibited in a dose-dependent manner (red triangles) by the
addition of a peptide that binds to S100B specifically, TRTK-12 (Table 1). The
same phage expressing S100B was also able to interact with a phage expressing
Hdm2 (λD-Hdm2K), and was also inhibited in a dose-dependent manner by
TRTK-12 (pink squares).
Fig. 6. Phosphorylation and acetylation in the C-terminus of p53 inhibits the
S100B–p53 interaction and prevents S100B-dependent down-regulation of the
tumor suppressor. These results are analogous to the mechanism for how
phosphorylation protects p53 from Hdm2-dependent degradation. (A) The
binding of unmodified p53367–393 peptide is compared to specifically
acetylated (Ac-K382) and phosphorylated (P-S376, P-T377, and P-S378)
forms of p53367–393. Phosphorylation (at positions S376, T377) and acetylation
(at position K382) inhibit the peptide binding to S100B via steric interactions
in accordance with the 3D structure of p53367–388 peptide bound to Ca2+–
S100B (shown in B) [86]. In (C), transient co-transfection of S100B with
either wild-type or specific alanine mutations of p53 at Ser-376 (S376A), Thr-
377 (T377A) or at both positions (S376A+T377A) are examined in H1299
cells (p53−/−). As observed previously, co-transfections of S100B with wild-
type p53 results in a decrease of p53 protein levels and its down-stream gene
product, p21, when compared to transient transfections of p53 alone ([25];
lanes 1, 2). However, when a double mutant of p53 (DM; S376A+T377A) is
transiently transfected into these same cells (+/−S100B; lanes 3, 4) and
compared to similar experiments with the corresponding single mutant proteins
(S376A, lanes 5, 6; T377A, lanes 7, 8), it is found that no additional effect is
observed with the S376A mutation (versus wild-type p53). These data indicate
that the T377A mutation is most deleterious and are consistent data from
Youmell et al., who reported that the T377A mutation had the largest effect on
p53-dependent transcription activation in cellular assays where these same
protein kinase C sites (PKC) were mutated [87] (see text).
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type p53 in human breast cancer cell line MCF-7 (p53+/+) [79]
was inhibited when transiently transfected with S100B [25].
These earlier data indicate that the basal levels of p53, Hdm2
and p21 can be induced by exposure to bleomycin [25], while
over-expression of S100B protein reduces p53 levels and its
downstream effector genes. Additional evidence that S100B
down-regulates p53 protein levels is provided by siRNA data
since when S100B levels are reduced using siRNA directed
against S100B (siRNAS100B), functional wild-type p53 protein
is restored in primary malignant melanoma cells [76].
It is well established that p53 activates the transcription of
Hdm2 (Fig. 7), a protein that is involved in ubiquitin-dependent
degradation of p53 itself as part of a feedback loop [33,45,80].
In an analogous situation to Hdm2, p53 also activates the
transcription of S100 proteins, including S100B [76,81]. The
promoter for S100B has six relatively equally spaced sequences
that correspond to the consensus sequence for p53 binding
(>16/20 nucleotide match), and one region has a nucleotide
sequence that matches the p53-binding consensus sequence
perfectly (20/20 nucleotide match). In DNA band shift binding
assays, regions of the S100B promoter bind p53 and, not
surprisingly, the constructs containing the 20/20 matching
sequence have the highest DNA binding affinity [25].
Furthermore, p53 activates transcription in reporter gene assays
(i.e. CAT assays) containing various constructs of the S100B
promoter [76].
It is now clear that the p53-dependent activation of the
S100B promoter is also itself negatively regulated. This
conclusion was first suspected from a comparison of the
transcription activity of the full-length S100B promoter to
Fig. 7. Scheme illustrating the down-regulation of p53 by the calcium-binding
protein S100B and the E3 ubiquitin ligase, Hdm2. In times of cellular stress,
covalent modifications (i.e. phosphorylation, blue circled P; acetylation, orange
circled Ac) of p53 protect the tumor suppressor from Hdm2- and S100B-
dependent binding in the N- and C-terminus of p53 (red oval) respectively, and
subsequent down-regulation of p53 protein levels. The interaction of S100B
with p53 requires that S100B binds calcium and undergoes a conformational
change (green circle→green hexagon). When p53 protein levels increase,
feedback control is in place since transcription of the S100B and Hdm2 genes
are both activated by elevated levels of p53 [76]. An interaction between S100B
and Hdm2was also detected as described here (Table 1; (Figs. 1, 2, 5)); however,
the cellular and mechanistic consequences of this interaction require further
investigation, so this newly discovered protein–protein interaction is repre-
sented by a dotted two-headed arrow.
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such as GADD45 [76]. While none of the GADD45 sites have a
20/20 matching sequence, this promoter is more highly
activated by p53 than the S100B promoter. Furthermore,
removing portions of the S100B promoter increases its p53-
dependent transcription activation, which is consistent with the
S100B promoter being negatively regulated when the full-
length promoter is intact. However, if the 20/20 p53 consensus
region of the S100B promoter is removed, then, not
surprisingly, the p53-dependent transcription activation activity
was diminished significantly [76]. Negative regulation of the
p53 region of the S100B promoter is logical because genes
involved in p53 function ought to be activated prior to genes
such as S100B and Hdm2, which ultimately negatively regulate
p53. In summary, like other proteins such as Pirh2 [82], COP1
[83] and Hdm2 that down regulate p53, S100B is also (i)
activated at the transcriptional level by p53 and (ii) then
subsequently inhibits p53 function via feedback control. The
important distinction between S100B and these other proteins is
that the S100B interaction with the C-terminus of p53 is Ca2+-
dependent and links p53 biology to extracellular growth
responses; whereas, Hdm2, COP1, and Pirh2 all interact more
towards the N-terminus of p53 than S100B and do not depend
on calcium for binding the tumor suppressor [61].
Overall, p53 is activated upon DNA damage or under stress
and up regulates the transcription of genes involved in apoptosis
(i.e. ↑Bax etc.) and cell cycle-dependent growth arrest (i.e. ↑p21
etc.) (Fig. 7). Under such conditions, it is now thought that p53
is protected from Hdm2 and S100B by covalent modification in
its transactivation domain and in its extreme C-terminus,
respectively (Figs. 6, 7). As part of a feedback controlmechanism, p53 also up regulates the transcription of genes
involved in its own inactivation (i.e. Hdm2 and S100B). In a
cell growth response, there is an increase in intracellular
calcium (↑Ca2+), and S100B binds calcium and undergoes a
conformational change as is necessary to interact with the tumor
suppressor protein, p53. This Ca2+-dependent interaction
between S100B and p53 induces a conformational change in
p53 and tetramer dissociation of the tumor suppressor [66],
which likely contributes to its degradation (i.e. perhaps
involving Hdm2/ubiquitin-and/or protease-dependent path-
ways). Thus, down-regulation of p53 by S100B and Hdm2
ultimately facilitates cell growth. The newly discovered
interaction described here between S100B and Hdm2 further
implies that these two proteins may work together to down-
regulate p53; however, the relevance of this interaction needs to
be explored in more detail in vivo. This interaction between
S100B and the E3 ligase for p53 ubiquitination, Hdm2, is
particularly intriguing because of precedence for an S100
protein, S100A6, interacting with an E3 ubiquitin ligase, now
called CacyBP/SIP; this E3 ubiquitin ligase, in turn, interacts
with Siah-1 and Skp1 and contributes to the ubiquitination and
degradation of beta-catenin [84,85].
The therapeutic relevance of inhibiting S100B is now
established because (i) S100B contributes to the depletion of
wild-type p53 protein in malignant melanoma and (ii) because
S100B protein levels are elevated in this and other cancers.
Therefore, such an effort to restore wild-type p53 tumor
suppressor function, as is typically found in melanoma, is now
underway using a rational drug design approach to find small
molecule inhibitors of S100B [70] that mimic, in some respects,
the activities observed previously with siRNA directed against
S100B [76]. The next step in this process is to fully understand
the target-binding site on S100B and how this site is different
from other S100 proteins. In this paper, the p53 binding site on
S100B is explored in detail, so that inhibitors can more readily
be prepared that bind S100B specifically. Furthermore, these
studies led to the discovery of a new and likely an important
protein–protein interaction between S100B and Hdm2 and
possibly with another regulator of p53, Hdm4. Lastly, data were
presented that show how cells may prevent the S100B–p53
interaction, via phosphorylation and acetylation. These data
suggest that the mechanism for the protection of the p53 tumor
suppressor from two of its known negative-regulatory proteins,
S100B and Hdm2, in vivo, is likely to be a very similar one (i.e.
via covalent modification of the tumor suppressor).
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